Austrália - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - nabam - fungicide - bowling and golf green turf - algae | spring dead spot | drechslera spp. | helminthosporium spp.

Austrália - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nuturf pty ltd - nabam - fungicide - bent lawn or turf | bowling and golf green turf | common couch lawn or turf | bermuda grass | established turf | green couch | i - algae | spring dead spot | drechslera spp. | helminthosporium spp.

Austrália - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

barmac industries pty ltd - nabam - fungicide - bowling green of bent grass | bowling green of common couch | croquet lawns | golf fairway of common couch | golf green of bent - algae | spring dead spot | drechslera spp. | helminthosporium spp.

Kolumbia - angličtina - Ecolab

ecolab deutschland gmbh -

Izrael - angličtina - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - tablets - gabapentin 600 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - tablets - gabapentin 800 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Spojené štáty - angličtina - NLM (National Library of Medicine)

direct rx - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 800 mg - controlled substance gabapentin is not a scheduled drug. abuse gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. a small number of postmarketing cases report gabapentin misuse and abuse. these individuals were taking higher than recommended doses of gabapentin for unapproved uses. most of the individuals described in these reports had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. when prescribing gabapentin carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g. development of tolerance, self-dose escalation, and drug-seeking behavior). dependence there are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. such symptoms included agitation, disorienta

Spojené štáty - angličtina - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 250 mg in 5 ml - gabapentin is indicated for the management of postherpetic neuralgia in adults. gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 to 12 years. gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. gabapentin is not a scheduled drug. gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. a small number of postmarketing cases report gabapentin misuse and abuse. these individuals were taking higher than recommended doses of gabapentin for unapproved uses. most of the individuals described in these reports had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. when prescribing gabapentin carefully ev

Spojené štáty - angličtina - NLM (National Library of Medicine)

west-ward pharmaceutical corp - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 100 mg - gabapentin capsules are indicated for the management of postherpetic neuralgia in adults. gabapentin capsules are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 - 12 years. gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. the abuse and dependence potential of gabapentin has not been evaluated in human studies.

Spojené štáty - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin 600 mg - gabapentin tablets, usp is indicated for: gabapentin tablets, usp are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy category c : there are no adequate and well-controlled studies in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic when administered to pregnant animals at doses similar to or lower than those used clinically. gabapentin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. when pregnant mice received oral doses of gabapentin (500 mg, 1000 mg, or 3000 mg/kg/day) during the period of organogenesis, embryo-fetal toxicity (increased incidences of skeletal variations) was observed at the two highest doses. the no-effect dose for embryo-fetal developmental toxicity in mice was 500 mg/kg/day or approximately ½ of the maximum recommended human dose (mrhd) of 3600 mg/kg on a body surface area (mg/m2 ) basis. in studies in which rats rece